June 19th, 2012

For Some Skin Cancers, Targeted Drug Hits the Mark

By

Modified dosing schedules may limit the side effects and are being investigated, noted Dr. Aleksandar Sekulic of the Mayo Clinic, who led the BCC study. In the phase II trial, 30 percent of patients with metastatic disease had a partial response, and 43 percent of patients with locally advanced disease had a complete or partial response. The study included 104 patients.

 

NCI Bulletin

Tags: complete response, dosing schedules, Dr. Aleksander Sekulic, NCI Bulletin, partial response, Preventive Medicine, Research

Contact Us · Privacy Policy